Search

Search Constraints

You searched for: Author/Creator Abrams, Ken

Search Results

1. 185 Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses. (25th April 2018)

2. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Issue 9 (6th June 2014)

3. Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome. Issue 1 (29th July 2016)

4. Canakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study. Issue 1 (7th June 2016)

5. Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Issue 1 (December 2017)

6. OP0055 EFFICACY OF CANAKINUMAB, ON A REDUCED DOSE OR A PROLONGED DOSE INTERVAL WITHOUT CONCOMITANT CORTICOSTEROIDS AND METHOTREXATE, IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS. (June 2019)

7. OP0114 MACHINE LEARNING TOOLS IDENTIFY PATIENT CLUSTERS AND SWOLLEN AND TENDER JOINT CORRELATION PATTERNS IN A LARGE DATABASE FROM THE SECUKINUMAB PSORIATIC ARTHRITIS CLINICAL DEVELOPMENT PROGRAM. (June 2019)

9. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. Issue 1 (January 2016)

10. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. Issue 1 (January 2016)